Screener / SEC EDGAR /CIK 0001588978 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Instruments

PROCEPT BioRobotics Corp PRCT

Compare with peers Embed
The 10-K against last year's

79 changes: 16 added, 11 removed, 51 reworded, 1 quiet changes

10-K Feb 26, 2026 vs Feb 27, 2025

10-K 0001588978-26-000009 (Feb 26, 2026) vs 10-K 0001588978-25-000007 (Feb 27, 2025) Not compared: Legal Proceedings.

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

456 paragraphs · 12 new · 80 reworded · 5 gone · 10-K Feb 26, 2026 against Feb 27, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 391 · 49% changed Every version of it
In addition, we may decide to abandon national and regional patent applications before they are granted. The examination of each national or regional patent application is an independent proceeding. As a result, patent applications in the same family may issue as patents in some jurisdictions, such as in the United States, but may issue as patents with claims of different scope or may even be refused in other jurisdictions. It is also quite common that depending on the country, the scope of patent protection may vary for the same product or technology. For example, certain jurisdictions do not allow for patent protection with respect to method of treatment.
Paragraph 321 · 48% changed Every version of it
The patent positions of medical device companies, including our patent position, may involve complex legal and factual questions that have been the subject of much litigation in recent years, and, therefore, the scope of any patent claims that we have or may obtain cannot be predicted with certainty. Accordingly, we cannot provide any assurances about which of our patent applications will issue, the breadth of any resulting patent, whether any of the issued patents will be found to be infringed, invalid or unenforceable or will be threatened or challenged by third parties, that any of our issued patents have, or that any of our currently pending or future patent applications that mature into issued patents will include, claims with a scope sufficient to protect our products and services. Our pending and future patent applications may not result in the issuance of patents or, if issued, may not issue in a form that will be advantageous to us. The coverage claimed in a patent application can be significantly reduced before the patent is issued. The scope of a patent may also be reinterpreted after issuance. The rights that may be granted under our future issued patents may not provide us with the proprietary protection or competitive advantages we are seeking.
Paragraph 413 · 46% changed Every version of it
Moreover, because of these fluctuations, comparing our operating results on a period-to-period basis may not be meaningful. You should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failure to meet the expectations of industry or financial analysts or investors for any period. If our revenues or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings forecasts that we may provide.
Paragraph 340 · 43% changed Every version of it
We may be subject to claims that current or former employees, collaborators or other third parties have an interest in our current or future patents, patent applications, trade secrets or other intellectual property rights as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our current or future products, services or technology. Although it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property rights to execute agreements assigning such intellectual property rights to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property rights that we regard as our own, and we cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property rights, and other owners may be able to license their rights to other third parties, including our competitors. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.
Paragraph 333 · 42% changed Every version of it
Decisions by courts and governmental patent agencies may introduce uncertainty in the enforceability or scope of patents and other intellectual properties owned by us. A court may decide that a patent or other intellectual property right of ours is invalid or unenforceable, in whole or in part, construe the patent’s claims or other intellectual property narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents or other intellectual property do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly.
Paragraph 189 · 40% changed Every version of it
In the United States, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system in ways that may harm our future revenues and profitability and the demand for our products. Federal and state lawmakers regularly propose and, at times, enact legislation that would result in significant changes to the healthcare system, some of which are intended to contain or reduce the costs of medical products and services. Current and future legislative and regulatory proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for the procedures associated with the use of our products. The cost containment measures that payors and providers are instituting and the effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our products.
Paragraph 118 · 38% changed Every version of it
Moreover, as a result of the broad scale release and availability of Artificial Intelligence (AI) technologies such as generative AI, there There is a global trend towards more regulation of AI technologies (e.g., the EU AI Act and AI laws passed in U.S. states) to ensure the ethical use, privacy, and security of AI and the data that it processes. Compliance with such laws will likely be an increasing and New or changing AI-related laws, regulations, or standards may require us to modify our business practices or products or incur substantial cost in the future. additional costs.
Paragraph 165 · 38% changed Every version of it
As a result of new administration The tariff policy environment has been and associated policy changes or shifting proposals by the U.S. government, there may can be greater restrictions and economic disincentives on international trade. For example, the U.S. government has pursued a new approach expected to trade policy, including renegotiating or terminating certain existing bilateral or multi-lateral trade agreements. It has also imposed tariffs on certain foreign goods and has raised the possibility of imposing significant, additional tariff increases or expanding the tariffs to capture other types of goods. These tariffs and other changes in U.S. trade policy have in the past and could continue to trigger retaliatory actions by affected countries, and certain foreign governments have instituted or are considering imposing retaliatory measures on certain U.S. goods. Foreign governments may also adopt other protectionist measures that could limit our ability to offer our products and services outside of the U.S. be dynamic. The ultimate impact of any these newly enacted and potential future tariffs or other restrictions on international trade will depend on various factors, including if any the ultimate levels of such tariffs, how long such tariffs are ultimately implemented, remain in place, and how other countries respond to the timing U.S. tariffs. While we manufacture our robotic systems and handpieces in California, we source certain components from foreign suppliers, including a third-party manufacturer of implementation, ultrasound systems and the amount, scope, nature of the tariffs, and corresponding actions by foreign governments. We, probes located in China. In addition, our suppliers and our customers also import certain raw materials, components and other products from foreign suppliers. Therefore, increased tariffs or other trade restrictions could increase the cost of our products and the components and raw materials that go into making them. These conditions may also require us to take additional risk mitigation measures that could result in increased costs. These increased costs could continue to adversely impact the gross margin that we earn on our products, which could make potentially making our products less competitive and reduce reducing consumer demand. In addition, some of our suppliers may experience disruption to their respective supply chains due to the broader impact of these tariffs, which could also negatively affect our cost of materials and timing of our production processes. As such, the increase of tariffs, the adoption and expansion of trade restrictions, the occurrence of a trade war, or other governmental action related to tariffs or trade agreements or policies has the potential to adversely impact demand for our products, our costs, our customers, our suppliers, and the United States economy, which in turn could have an adverse effect on our business, financial condition and results of operations.

MD&A

85 paragraphs · 4 new · 25 reworded · 6 gone · 10-K Feb 26, 2026 against Feb 27, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 9 · 49% changed
•Grow our install base of robotic systems: As of December 31, 2024, 2025, we had an install base of 647 912 robotic systems globally, including 505 718 in the United States. In the United States, we are initially focused on driving adoption of Aquablation therapy among urologists that perform hospital-based resective BPH surgery. We target approximately 2,700 hospitals that perform resective BPH procedures in the United States. To penetrate these hospitals, we expect to continue to increase our direct team of capital sales representatives, who are focused on driving system placement within hospitals by engaging with key surgeons and decision makers to educate them about the compelling value proposition of Aquablation therapy. As we increase our install base of robotic systems, we expect our revenue to increase as a result of the system sale and resulting utilization.
Paragraph 80 · 35% changed
Expected Volatility. Since there has been limited public market for our common stock and limited company specific company-specific historical volatility, we have determined the share our expected stock price volatility assumptions were determined using a blended volatility, by examining the historical volatilities for options granted based on an analysis of industry peers and the volatility of a peer group of publicly traded companies. the Company’s stock following our initial public offering. In evaluating similarity, similar peers, we consider factors such as industry, stage of life cycle and size.
Paragraph 33 · 33% changed
Interest expense of $4.2 $3.6 million during the year ended December 31, 2024 remained relatively flat 2025 decreased $0.6 million or 14% compared to fiscal 2023. 2024. The decrease was primarily due to decreases in interest rates during the year.
Paragraph 22 · 29% changed
Selling, general and administrative, or SG&A, expenses include consist primarily of compensation for personnel, including stock-based compensation, related to selling, marketing, clinical affairs, professional education, finance, information technology, and human resource functions. SG&A expenses also include commissions, training, travel expenses, promotional activities, conferences, trade shows, professional services fees, audit fees, legal fees, insurance costs costs, bad debt expense and general corporate expenses including allocated facilities-related expenses. Post-market clinical study expenses include trial design, site reimbursement, data management and travel expenses. We expect our SG&A expenses to increase in absolute dollars for the foreseeable future as we expand our commercial infrastructure and incur additional fees associated with operating in order for us to execute on our long-term growth plan, though it may fluctuate from quarter to quarter. However, over time, we expect our SG&A expenses to decrease as a public company, including legal, accounting, insurance, compliance with the rules and regulations percentage of the SEC and those of revenue.
Paragraph 35 · 26% changed
As of December 31, 2024, 2025, we had cash and cash equivalents of $333.7 $286.5 million, an accumulated deficit of $546.0 $641.6 million, and $52.0 million outstanding on our loan facility. We expect our expenses will increase for the foreseeable future, as we continue to make substantial investments in sales and marketing, operations and research and development. Moreover, we expect to incur additional expenses as a result of operating as a public company, including legal, accounting, insurance, compliance with the rules and regulations of the SEC and those of any stock exchange on which our securities are traded, investor relations, and other administrative and professional services expenses. Our future funding requirements will depend on many factors, including:
Paragraph 34 · 25% changed
Interest and other income, net, increased $2.1 $2.3 million to $9.4 $12.1 million during the year ended December 31, 2024 2025 compared to $7.3 $9.8 million during the year ended December 31, 2023. 2024. The increase in interest and other income, net was primarily due to higher an increase in average cash balances during the year, partially offset by decreases in interest rates earned on our cash equivalents. rates.
Paragraph 45 · 23% changed
In October 2022, we entered into a loan and security agreement with Canadian Imperial Bank of Commerce. The Agreement agreement provides for a senior secured term loan facility in the aggregate principal amount of $52.0 million, million (the “Term Loan Facility”), which was borrowed in full. Proceeds from the term loan facility were used to repay and terminate our previous loan facility, transaction fees, and related expenses.
Paragraph 48 · 23% changed
The obligations under the loan and security agreement are secured by substantially all of our assets, including its intellectual property and by a pledge all of our equity interests in its U.S. subsidiaries and 65% of our equity interests in its non-U.S. subsidiaries that are directly owned by us. We are obligated to maintain in deposit accounts held at the lender equal to at least the lesser of (i) $100.0 million or (ii) all of our non-operating cash.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors299 words changed in this paragraph; it is 50% similar to last year's version.
As a result of new administration The tariff policy environment has been and associated policy changes or shifting proposals by the U.S. government, there may can be greater restrictions and economic disincentives on international trade. For example, the U.S. government has pursued a new approach expected to trade policy, including renegotiating or terminating certain existing bilateral or multi-lateral trade agreements. It has also imposed tariffs on certain foreign goods and has raised the possibility of imposing significant, additional tariff increases or expanding the tariffs to capture other types of goods. These tariffs and other changes in U.S. trade policy have in the past and could continue to trigger retaliatory actions by affected countries, and certain foreign governments have instituted or are considering imposing retaliatory measures on certain U.S. goods. Foreign governments may also adopt other protectionist measures that could limit our ability to offer our products and services outside of the U.S. be dynamic. The ultimate impact of any these newly enacted and potential future tariffs or other restrictions on international trade will depend on various factors, including if any the ultimate levels of such tariffs, how long such tariffs are ultimately implemented, remain in place, and how other countries respond to the timing U.S. tariffs. While we manufacture our robotic systems and handpieces in California, we source certain components from foreign suppliers, including a third-party manufacturer of implementation, ultrasound systems and the amount, scope, nature of the tariffs, and corresponding actions by foreign governments. We, probes located in China. In addition, our suppliers and our customers also import certain raw materials, components and other products from foreign suppliers. Therefore, increased tariffs or other trade restrictions could increase the cost of our products and the components and raw materials that go into making them. These conditions may also require us to take additional risk mitigation measures that could result in increased costs. These increased costs could continue to adversely impact the gross margin that we earn on our products, which could make potentially making our products less competitive and reduce reducing consumer demand. In addition, some of our suppliers may experience disruption to their respective supply chains due to the broader impact of these tariffs, which could also negatively affect our cost of materials and timing of our production processes. As such, the increase of tariffs, the adoption and expansion of trade restrictions, the occurrence of a trade war, or other governmental action related to tariffs or trade agreements or policies has the potential to adversely impact demand for our products, our costs, our customers, our suppliers, and the United States economy, which in turn could have an adverse effect on our business, financial condition and results of operations.

Source: Item 1A, 10-K 0001588978-26-000009 vs Item 1A, 10-K 0001588978-25-000007

MD&A121 words changed in this paragraph; it is 38% similar to last year's version.
The term loan facility Term Loan Facility is scheduled to mature on October 6, 2027, the fifth anniversary of the Closing Date (the “Maturity Date”). The loan and security agreement provides for interest-only payments on the term loan facility for the first thirty-six months following the Closing Date (the “Initial Interest-Only Period”). The Initial Interest-Only Period will be extended to an additional twelve months if we achieve either (i) $200.0 million closing date, or greater in revenue in any twelve-month period or (ii) $0 or greater in EBITDA in any six-month period. Thereafter, amortization payments on the Term Loan Facility will be payable monthly until the Maturity Date in monthly installments equal to 20% of the then outstanding principal amount of the Term Loan Facility divided by 12 plus any accrued and unpaid interest. Date. We have the option to prepay the Term Loan Facility without any prepayment charge or fee. We achieved the twelve-month revenue target as of December 31, 2024.

Source: Item 7, 10-K 0001588978-26-000009 vs Item 7, 10-K 0001588978-25-000007

Accounting Policies117 words changed in this paragraph; it is 72% similar to last year's version.
In connection with the Company’s previous loan facility (Note 6), the Company is obligated to pay a fee upon the earlier occurrence of a defined liquidity event, including but not limited to, a merger or sale of our assets or voting stock, or achieving a $200.0 million trailing 12 months revenue target, in each case, by September 2029. The fee is calculated at the time of the liquidity event occurrence to be $1.0 million if only the first installment has been drawn, $2.0 million if the first two installments have been drawn, $2.4 million if the first three installments have been drawn, or $3.0 million if all four installments have been drawn, in each case, upon the occurrence of the liquidity event. At the time of extinguishment, the Company has drawn on the first two installments. The Company has determined this fee is a freestanding derivative instrument. The $2.0 million fair value of this loan facility derivative was initially recorded as a debt discount and a current liability on the date of issuance in connection with obtaining additional financing as applicable and will be revalued every reporting period until the earlier occurrence of a defined liquidity event or achieving a revenue target by September 2029 or termination of such fee arrangement. At December 31, 2024, the Company achieved the 12 month revenue target. As a result, The outstanding balance was paid in full during the loan facility derivative became due and will no longer be revalued. The Company has recorded the amount due as a current liability in the Company’s consolidated balance sheets. second fiscal quarter of 2025.

Source: Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001588978-26-000009 vs Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001588978-25-000007

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of PRCT's Risk Factors and MD&A, 10-K Feb 26, 2026 against 10-K Feb 27, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
The use of artificial intelligence in our business, including in our products and internally by our employees or business partners, may expose us to additional legal, regulatory and other risks that could adversely affect our business.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
We use, and may continue to expand our use of, artificial intelligence (“AI”) technologies in our products and operations. For example, our HYDROS Robotic System includes AI-enabled, imaging-related assistive functionality designed to support Aquablation therapy. AI technologies are complex and rapidly evolving, and AI-enabled functionality may produce outputs that are inaccurate, incomplete, misleading, or biased, and could adversely affect our business.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
In addition, our employees, contractors, and other third parties with whom we do business may use AI tools, including generative AI tools provided by third parties, in the course of their work. Such use may increase the risk that confidential, proprietary, or sensitive business information is inadvertently disclosed or incorporated into third-party systems, or that the security of our internal IT systems could be compromised. Although we have adopted policies, training, contractual restrictions, and technical controls intended to govern the use of AI tools and mitigate these risks, we cannot assure you that such measures will be effective in all instances.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
Foreign data protection laws, including the General Data Protection Regulation, including as implemented in the United Kingdom, or collectively or GDPR, may also apply to our processing of health-related and other personal data
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
the future, or delays in entering into new strategic partnership agreements could delay tour sales and marketing efforts, which would harm our business prospects, financial condition and results of operations.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
As a result of new administration and associated policy changes or shifting proposals by the U.S. government, there may be greater restrictions and economic disincentives on international trade. For example, the U.S. government has pursued a new approach to trade policy, including renegotiating or terminating certain existing bilateral or multi-lateral trade agreements. Beginning in 2025, the U.S. government has imposed significant new tariffs on imports, which, along
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
with other U.S. trade actions, have triggered retaliatory actions by certain affected countries, including retaliatory measures on U.S. goods and other protectionist measures that could limit our ability to offer our products and services outside of the U.S.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
business. In addition, an organization that fails to prevent bribery by anyone associated with the organization can be charged under the Bribery Act, unless the organization can establish the defense of having implemented adequate procedures to prevent bribery.
Read it in 10-K Feb 26, 2026 at sec.gov
Show the other 44
AddedRisk Factors
and financial resources, expose us to product liability or other claims, harm our reputation with customers and adversely impact our business, financial condition and results of operations.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
adverse effect on our business. Any of the foregoing may cause us to incur substantial costs, and could place a significant strain on our financial resources, divert the attention of management from our core business and harm our reputation.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
In addition, we may need to obtain additional licenses from our existing licensors and others to allow commercialization of products we may develop. Moreover, we may be required to expend significant time and resources to
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
Section 404 of the Sarbanes-Oxley Act requires that we maintain effective internal control over financial reporting and disclosure controls and procedures. In particular, we must perform system and process evaluations, document our controls
Read it in 10-K Feb 26, 2026 at sec.gov
RemovedRisk Factors
and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
reduced Medicare payments to several categories of healthcare providers, including hospitals, and increased the statute of limitations period for the government to recover Medicare overpayments to providers from three to five years.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
Initiating and completing clinical trials necessary to support any future PMA applications or de novo requests, or to provide additional safety and efficacy data beyond those typically required for a 510(k) clearance, for our possible future
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
We rely in part on our portfolio of issued patents and pending patent applications in the United States and other countries to protect our intellectual property and competitive position. However, our patent applications may not result in issued patents, and any patents that are issued may not provide meaningful protection against competitors or competitive technologies. Further, the examination process may require us to narrow the claims for our pending patent applications, which may limit the scope of patent protection that may be obtained if these applications issue. It is also possible that we
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. These provisions may also result in increased costs for investors seeking to bring a claim against us or any of our directors, officers or other employees.
Read it in 10-K Feb 27, 2025 at sec.gov
RewordedRisk Factors
As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
The intellectual property laws and other statutory and contractual arrangements in the United States and other jurisdictions we depend upon may not provide sufficient protection in the future to prevent the infringement, use, violation or misappropriation of our patents, trademarks, data, technology and other intellectual property rights, products and services, and may not provide an adequate remedy if our intellectual property rights are infringed, misappropriated or otherwise violated. violated, including in connection with our use of AI, as intellectual property protection in the field of AI is evolving and there is uncertainty regarding the degree and extent of protection that may be available for AI technologies and related system inputs and outputs.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
If the FDA disagrees with our determination and requires us to submit new 510(k) notifications or PMA applications for modifications to our previously cleared products for which we have concluded that new clearances or approvals are unnecessary, we may be required to cease marketing or to recall the modified product until we obtain clearance or approval, and we may be subject to significant regulatory fines or penalties.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Moreover, as a result of the broad scale release and availability of Artificial Intelligence (AI) technologies such as generative AI, there There is a global trend towards more regulation of AI technologies (e.g., the EU AI Act and AI laws passed in U.S. states) to ensure the ethical use, privacy, and security of AI and the data that it processes.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
If we fail to maintain necessary marketing authorizations for our robotic systems, or if approvals or clearances for future products or modifications to existing products are delayed or not issued, it will negatively affect our business, financial condition and results of operations.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Any provision of our amended and restated certificate of incorporation currently in effect or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
We rely on a combination of contractual provisions, confidentiality procedures and patent, trade secret, copyright and trademark laws to protect our proprietary technology, products, services, brands, trade secrets, know-how and data and prevent others from duplicating our robotic systems or its disposable components, and our other current and future products, services and technology.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
A loss of key personnel or their work product could hamper or prevent our ability to commercialize our product, which could have an adverse effect on our business, financial condition and results of operations.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Any person or entity purchasing or otherwise acquiring any interest in our shares of capital stock shall be deemed to have notice of and consented to this exclusive forum provision, but will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Any Moreover, any change in the laws or regulations pursued by the current presidential administration and Congress that govern the clearance and approval processes relating to our current and future products products, including with respect to FDA regulations, could make it more difficult and costly to obtain clearance or approval for new products, or to produce, market and distribute existing products.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Current and future legislative and regulatory proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for the procedures associated with the use of our products.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
The provision for income taxes consists primarily of foreign income taxes, as the Company does not have U.S. federal or state taxable income for the periods presented. As we expand the scale of our international business activities, any changes in the United States and foreign taxation of such activities may increase our overall provision for income taxes in the future. We have a valuation allowance for our United States deferred tax assets, including federal and state non-operating loss carryforwards. We expect to maintain this valuation allowance until it becomes more likely than not that the benefit of our federal and state deferred tax assets will be realized by way of expected future taxable income in the United States.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
The Term Loan Facility is scheduled to mature on October 6, 2027, the fifth anniversary of the closing date, or the Maturity Date. We have the option to prepay the Term Loan Facility without any prepayment charge or fee.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
In August 2025, we entered into a second amendment to the loan and security agreement (the “Second Amendment”), which, among other things, modified the repayment terms such that the entire principal amount outstanding is now due on the Maturity Date, replacing the prior repayment schedule of interest-only payments followed by monthly principal amortization payments. After giving effect to the Second Amendment, we are obligated to maintain in collateral accounts held at the lender (a) if our cash and cash equivalents is less than $50.0 million, 100% of our cash and cash equivalents; or (b) if our cash and cash equivalents is greater than or equal to $50.0 million, the greater of (i) $50.0 million or (ii) 50% of our cash and cash equivalents, with amounts exceeding $50.0 million permitted to be held outside of the lender in collateral accounts managed by the lender.
Read it in 10-K Feb 26, 2026 at sec.gov
RemovedMD&A
any stock exchange on which our securities are traded, investor relations, and other administrative and professional services expenses, though it may fluctuate from quarter to quarter. However, over time, we expect our SG&A expenses to decrease as a percentage of revenue.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
We completed a follow-on offering of common stock in October 2024, which raised $164.5 million in proceeds to us, net of issuance costs. Previously, our primary sources of capital have been from our initial public offering, private placements of redeemable convertible preferred securities and debt financing agreements.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
The term loan facility is scheduled to mature on October 6, 2027, the fifth anniversary of the Closing Date (the “Maturity Date”). The loan and security agreement provides for interest-only payments on the term loan facility for the first thirty-six months following the Closing Date (the “Initial Interest-Only Period”). The Initial Interest-Only Period will be extended to an additional twelve months if we achieve either (i) $200.0 million or greater in revenue in any twelve-month period or (ii) $0 or greater in EBITDA in any six-month period. Thereafter, amortization payments on the Term Loan Facility will be payable monthly until the Maturity Date in monthly installments equal to 20% of the then outstanding principal amount of the Term Loan Facility divided by 12 plus any accrued and unpaid interest. We have the option to prepay the Term Loan Facility without any prepayment charge or fee. We achieved the twelve-month revenue target as of December 31, 2024.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
We have determined that our obligation to pay success fees to a lender upon a successful liquidation event or achieving a revenue target represents freestanding financial instruments. The instrument is classified as a current liability in the consolidated balance sheets and is subject to remeasurement at each consolidated balance sheet date. Any change in fair value is recognized through other income (expense) in the consolidated statements of operations and comprehensive loss. We adjust the carrying values of the loan facility derivative liability for changes in fair value and will continue to do so until the earlier of cash payment or expiration. The assumptions used in determining the fair value of the obligation require significant judgment.
Read it in 10-K Feb 27, 2025 at sec.gov
RewordedMD&A
During the year ended December 31, 2024, 2025, net cash provided by financing activities was $180.1 $11.2 million, consisting primarily of proceeds of $4.8 million from the exercise of stock options and proceeds of $6.4 million from the issuance of common stock of $164.5 million, net of issuance costs, and proceeds of $11.1 million from under the exercise of employee stock options. purchase plan.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Cost of sales increased $22.3 $24.4 million, or 34%, 28%, to $111.8 million during the year ended December 31, 2025, compared to $87.4 million during the year ended December 31, 2024, compared to $65.1 million during the year ended December 31, 2023. 2024.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
R&D expenses increased $13.9 $9.0 million, or 29%, 14%, to $71.3 million during the year ended December 31, 2025, compared to $62.3 million during the year ended December 31, 2024, compared to $48.4 million during the year ended December 31, 2023. 2024.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Operating activities $ (48,985) $ (99,213) $ (108,003) $ (80,382) Investing activities (9,356) (4,409) (25,206) (2,653) Financing activities 11,193 180,125 167,795 3,612 Effect of exchange rates on cash, cash equivalents and restricted cash (74) — — Net increase (decrease) in cash, cash equivalents and restricted cash $ (47,222) $ 76,503 $ 34,586 $ (79,423)
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
However, over time, we expect our R&D expenses to decrease as a percentage of revenue to vary over time depending on the level and timing of initiating new product development efforts. revenue.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
The increase in interest and other income, net was primarily due to higher an increase in average cash balances during the year, partially offset by decreases in interest rates earned on our cash equivalents. rates.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
The increase in R&D expenses was primarily due to employee-related expenses from increased headcount of our R&D organization, organization such as well as increases in third-party product development costs. salaries and wages and stock-based compensation.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
The expansion of our commercialization activities resulted in increases in inventory, accounts receivable, prepaid expenses and other current assets along with long-term assets, a decrease in accounts payable, partially offset by an increase in accrued compensation, deferred revenue, lease other accrued liabilities, and accrued interest expense.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
We expect our R&D expenses to increase in absolute dollars for the foreseeable future as we make strategic investments in R&D, continue to develop, develop and enhance and commercialize new existing products and technologies, though it may fluctuate from quarter to quarter.
Read it in 10-K Feb 26, 2026 at sec.gov
Quiet changesMD&A
Selling, general and administrative, or SG&A, expenses include consist primarily of compensation for personnel, including stock-based compensation, related to selling, marketing, clinical affairs, professional education, finance, information technology, and human resource functions.
Read it in 10-K Feb 26, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PRCT/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.